Addex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment.
Charles River Laboratories has acquired two of Tigermed’s Frontage laboratory sites in Pennsylvania for $470 million upfront ...
While Kyverna awaits an FDA decision on whether to grant the first-ever approval for an autoimmune CAR-T therapy, the biotech ...
The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post ...
Vor Bio is paying RemeGen $10 million upfront in cash and issuing warrants valued at approximately $46 million for rights to RC298 outside Greater China, adding a long-acting drug ...
Boehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its ...
Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late ...
PepGen’s phase 2 myotonic dystrophy type 1 (DM1) data have met analysts’ best-case scenario, causing the biotech’s share ...
AstraZeneca has acquired vaccine bioconjugation specialist Omn | AstraZeneca has acquired vaccine bioconjugation specialist ...
Generate Biomedicines' CEO has hailed the “huge opportunity” offered by AI tools after the Flagship-founded company used ...
Windward Bio is sailing toward the public markets with the aim of wafting in over $200 million in proceeds to fund two ...
Argenx has struck a deal to acquire Unnatural Products (UNP) for $550 million upfront, snapping up the Merck & Co.- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results